Last synced on 27 January 2023 at 11:04 pm

Implantable Transprostatic Tissue Retractor System

Page Type
Product Code
Definition
The treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men age 50 and above.
Physical State
Comprises two main components, the delivery device and implant. Each delivery device comes pre-loaded with one I\implant. The delivery device is inserted into a 20F cystoscopy sheath which has been placed in the male urethra with the sheath tip located within the bladder. After insertion into the sheath, the tip of the device is positioned in the prostatic urethra and used to retract an obstructing prostatic lobe. An implant is then deployed transversely through the urethra into the prostatic tissue. The implant is secured to maintain the retracted position of the lobe. Implants are deployed thereby maintaining an expanded urethral lumen.
Technical Method
Delivered transurethrally using a rigid delivery device which is used to displace the urethra towards the prostatic capsule. The implants then maintain the approximated position of the inner (urethral) tissue and the outer (capsular) tissue of the prostate thereby reducing fluid obstruction and improving LUTS. The displaced urethra then provides increased urethral opening. The biological mechanism of action is localized transient tissue compression leading to lobular atrophy. Once lobular atrophy has been obtained, the static implant imparts no further mechanical stimulation on the tissue, and tissue remodeling is complete.
Target Area
Prostate
Regulation Medical Specialty
Gastroenterology and Urology
Review Panel
Gastroenterology and Urology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
876.5530
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
Yes
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 876.5530 Implantable transprostatic tissue retractor system

§ 876.5530 Implantable transprostatic tissue retractor system.

(a) Identification. An implantable transprostatic tissue retractor system is a prescription use device that consists of a delivery device and implant. The delivery device is inserted transurethrally and deploys the implant through the prostate. It is designed to increase prostatic urethral patency by providing prostate lobe tissue retraction while preserving the potential for future prostate procedures and is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia in men.

(b) Classification. Class II (special controls). The special controls for this device are:

(1) The elements of the device that may contact the patient must be demonstrated to be biocompatible.

(2) Performance data must demonstrate the sterility of the patient-contacting components of the device.

(3) Performance data must support shelf life by demonstrating continued sterility of the device (of the patient-contacting components), package integrity, and device functionality over the requested shelf life.

(4) Non-clinical testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:

(i) Deployment testing must be conducted.

(ii) Mechanical strength must be conducted.

(iii) Resistance-to-degradation testing must be conducted.

(5) Non-clinical testing must evaluate the compatibility of the device in a magnetic resonance environment.

(6) In vivo testing must demonstrate safe and effective use, assess the impact of the implants on the ability to perform subsequent treatments, document the adverse event profile associated with clinical use, and demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:

(i) Deployment testing must be conducted.

(ii) Implant migration must be conducted.

(7) Labeling must bear all information required for safe and effective use of the device, and must include:

(i) Specific instructions, warnings, cautions, limitations, and the clinical training needed for the safe use of the device.

(ii) Information on the patient population for which the device has been demonstrated to be effective.

(iii) A detailed summary of the device technical parameters.

(iv) Information on how the device operates and the typical course of treatment.

(v) An expiration date/shelf life.

(vi) A detailed summary of the device- and procedure-related complications or adverse events pertinent to use of the device.

[79 FR 43249, July 25, 2014]

Implantable Transprostatic Tissue Retractor System

Page Type
Product Code
Definition
The treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men age 50 and above.
Physical State
Comprises two main components, the delivery device and implant. Each delivery device comes pre-loaded with one I\implant. The delivery device is inserted into a 20F cystoscopy sheath which has been placed in the male urethra with the sheath tip located within the bladder. After insertion into the sheath, the tip of the device is positioned in the prostatic urethra and used to retract an obstructing prostatic lobe. An implant is then deployed transversely through the urethra into the prostatic tissue. The implant is secured to maintain the retracted position of the lobe. Implants are deployed thereby maintaining an expanded urethral lumen.
Technical Method
Delivered transurethrally using a rigid delivery device which is used to displace the urethra towards the prostatic capsule. The implants then maintain the approximated position of the inner (urethral) tissue and the outer (capsular) tissue of the prostate thereby reducing fluid obstruction and improving LUTS. The displaced urethra then provides increased urethral opening. The biological mechanism of action is localized transient tissue compression leading to lobular atrophy. Once lobular atrophy has been obtained, the static implant imparts no further mechanical stimulation on the tissue, and tissue remodeling is complete.
Target Area
Prostate
Regulation Medical Specialty
Gastroenterology and Urology
Review Panel
Gastroenterology and Urology
Submission Type
510(K)
Device Classification
Class 2
Regulation Number
876.5530
GMP Exempt?
No
Summary Malfunction Reporting
Eligible
Implanted Device
Yes
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

CFR § 876.5530 Implantable transprostatic tissue retractor system

§ 876.5530 Implantable transprostatic tissue retractor system.

(a) Identification. An implantable transprostatic tissue retractor system is a prescription use device that consists of a delivery device and implant. The delivery device is inserted transurethrally and deploys the implant through the prostate. It is designed to increase prostatic urethral patency by providing prostate lobe tissue retraction while preserving the potential for future prostate procedures and is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia in men.

(b) Classification. Class II (special controls). The special controls for this device are:

(1) The elements of the device that may contact the patient must be demonstrated to be biocompatible.

(2) Performance data must demonstrate the sterility of the patient-contacting components of the device.

(3) Performance data must support shelf life by demonstrating continued sterility of the device (of the patient-contacting components), package integrity, and device functionality over the requested shelf life.

(4) Non-clinical testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:

(i) Deployment testing must be conducted.

(ii) Mechanical strength must be conducted.

(iii) Resistance-to-degradation testing must be conducted.

(5) Non-clinical testing must evaluate the compatibility of the device in a magnetic resonance environment.

(6) In vivo testing must demonstrate safe and effective use, assess the impact of the implants on the ability to perform subsequent treatments, document the adverse event profile associated with clinical use, and demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:

(i) Deployment testing must be conducted.

(ii) Implant migration must be conducted.

(7) Labeling must bear all information required for safe and effective use of the device, and must include:

(i) Specific instructions, warnings, cautions, limitations, and the clinical training needed for the safe use of the device.

(ii) Information on the patient population for which the device has been demonstrated to be effective.

(iii) A detailed summary of the device technical parameters.

(iv) Information on how the device operates and the typical course of treatment.

(v) An expiration date/shelf life.

(vi) A detailed summary of the device- and procedure-related complications or adverse events pertinent to use of the device.

[79 FR 43249, July 25, 2014]